Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
03 April 2018 Photo Sonia Small
First-rate fund managers in SA produced by UFS Prof Philippe Burger
of Philippe Burger, Acting Dean of the Faculty of Economic and Management Science.
A recent comparative study on the performance of South African fund managers has revealed that the-top performing fund managers over a running average of five years are former undergraduate students of the University of the Free State (UFS).

In an attempt to understand South Africa’s fund managers, Leigh Köhler, head of research at Glacier by Sanlam, and his team, published a comprehensive breakdown which looked at all South African universities and universities of technology. Aspects explored in the report included philosophy, process, people, organisational structure, and cost of funds. In addition, the study also considered characteristics such as age, tenure, level of qualification and undergraduate university to identify fund managers who are superior to their peers.

A closer look at the statistics
The majority of the sampled fund managers studied at the University of Cape Town (46%), University of Stellenbosch (10%), and University of the Witwatersrand (8%), while only 2% studied at the UFS. However, according to the report, “The highest average performance over five years was generated by fund managers who attended the UFS – 13.25%.” This means that for every rand they invested, the portfolios managed by UFS alumni got back approximately R1.13 annually, the highest return when compared to the returns generated by portfolio managers from other universities. These fund managers are employed by a range of institutions, including independent asset management firms, insurance companies, banks and wealth managers.

What our acting dean had to say
Prof Philippe Burger, Acting Dean at the UFS Faculty of Economic and Management Science, said: “When you and I put money into a pension fund or investment, portfolio managers buy bonds and shares with it from companies. Those companies use that money to invest in building factories, businesses, offices, and of course they make a profit on their investments. That profit is used to pay interest and dividends. These interest payments, dividends and increased share values constitute the returns paid to investors.”

The outstanding performance of UFS-groomed fund managers is a comment on the quality of the students UFS delivers. “For decades we have had a BComm degree that includes an option to specialise in what was previously called Money and Banking, and is now called Financial Economics. We are the only faculty that has had a focus on Financial Economics going back all the way to the late 1970s. In that sense we train people and give them an education that allows them to perform like this,” said Prof Burger. 

Moving forward, the faculty is looking at partnerships with financial institutions that can strengthen that capacity and give students increased value for money. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept